Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Vassallo M; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Goldberg JD; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.; Division of Biostatistics, NYU Grossman School of Medicine, New York, New York, USA., Eroglu Z; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Kim Y; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA., Cao B; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA., Ferguson R; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Monson KR; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Kirchhoff T; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Amato CM; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA., Burke P; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA., Strange A; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA., Monk E; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA., Gibney GT; Lombardi Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA., Kudchadkar R; Division of Hematology-Oncology, Winship Cancer Center, Emory University School of Medicine Atlanta, Atlanta, Georgia, USA., Markowitz J; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Brohl AS; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Pavlick A; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Richards A; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Woods DM; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA., Weber J; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA Jeffrey.Weber@nyulangone.org.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Nov; Vol. 10 (11).
Autor:
Hodi FS; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chapman PB; Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Sznol M; Medical Oncology, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, Connecticut., Lao CD; Dermatology, University of Michigan, Ann Arbor, Michigan., Gonzalez R; Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA., Smylie M; Medical Oncology and Clinical Research, Cross Cancer Institute, Edmonton, Alberta, Canada., Daniels GA; Medical Oncology, UC San Diego Health - La Jolla, La Jolla, California., Thompson JA; Phase 1 Clinical Trials Program, Seattle Cancer Care Alliance, Seattle, Washington., Kudchadkar R; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Sharfman W; Cutaneous Oncology, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, Maryland., Atkins M; Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington DC., Spigel DR; Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee., Pavlick A; Medical Oncology, Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, USA., Monzon J; Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada., Kim KB; Medical Oncology, California Pacific Medical Center Research Institute, San Francisco, California, USA., Ernst S; Medical Oncology, London Health Sciences Centre, London, Ontario, Canada., Khushalani NI; Cutaneous Oncology, H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., van Dijck W; Bristol Myers Squibb, Princeton, New Jersey, USA., Lobo M; Bristol Myers Squibb, Princeton, New Jersey, USA., Hogg D; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Publikováno v:
Melanoma research [Melanoma Res] 2021 Feb 01; Vol. 31 (1), pp. 67-75.
Autor:
Michael A. Postow, Peter A. Forsyth, Hussein Abdul-Hassan Tawbi, Igor Puzanov, Ahmad A. Tarhini, Jasmine I. Rizzo, Alain Algazi, F. Stephen Hodi, Omid Hamid, Anna C. Pavlick, Sekwon Jang, Ragini R. Kudchadkar, Christopher D. Lao, Karl D. Lewis, David A. Reardon, Nikhil I. Khushalani, Stergios J. Moschos, Kim Margolin, John A. Glaspy, Reena Thomas, Anne Sumbul, Michael B. Atkins, M. S. Ernstoff
Publikováno v:
Neuro-Oncology
Neuro Oncol
Neuro-oncology, vol 23, iss 11
Neuro Oncol
Neuro-oncology, vol 23, iss 11
Background In patients with melanoma and asymptomatic brain metastases (MBM), nivolumab plus ipilimumab provided an intracranial response rate of 55%. Here, we present the first report for patients who were symptomatic and/or required corticosteroids
Autor:
Ragini R. Kudchadkar, John A. Thompson, Wim van Dijck, Michael Smylie, David Hogg, Kevin B. Kim, Maurice Lobo, Gregory A. Daniels, Anna C. Pavlick, Mario Sznol, David R. Spigel, Scott Ernst, Rene Gonzalez, Nikhil I. Khushalani, Christopher D. Lao, F. Stephen Hodi, Paul B. Chapman, William H. Sharfman, Michael B. Atkins, Jose Gerard Monzon
Publikováno v:
Melanoma Research
Supplemental Digital Content is available in the text.
CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in cl
CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in cl
Autor:
Vanna Chiarion-Sileni, Pablo Luis Ortiz Romero, Daniil Stroyakovskiy, Rosalie Fisher, Alexander M.M. Eggermont, James Larkin, Paul Lorigan, Axel Hauschild, Micaela Hernberg, Mario Mandalà, Alexander J C van Akkooi, Michal Kicinski, Susana Puig, Nageatte Ibrahim, Lars Bastholt, Victoria Atkinson, Peter Hersey, Pietro Quaglino, Shahneen Sandhu, Christian U. Blank, Georgina V. Long, Anna Maria Di Giacomo, Andrey Meshcheryakov, Naoya Yamazaki, Stefan Suciu, Sandrine Marreaud, Peter Mohr, Ragini R. Kudchadkar, Inge Marie Svane, Matthew Strother, Clemens Krepler, Caroline Robert, Paola Queirolo, Catherine Barrow
Publikováno v:
Eggermont, A MM, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A CJ, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Background: In the phase III double-blind European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 trial, pembrolizumab improved recurrence free and distant metastasis-free survival in patients with stage III cutaneous melanoma wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206bf54251ce7ab0bcaf3dc33467c927
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdf
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdf
Autor:
Margarita Askelson, Igor Puzanov, Ragini R. Kudchadkar, Alain Algazi, Michael A. Postow, Omid Hamid, Nikhil I. Khushalani, Anna C. Pavlick, Karl D. Lewis, Hussein Abdul-Hassan Tawbi, John A. Glaspy, Christopher D. Lao, Kim Margolin, F. Stephen Hodi, Stergios J. Moschos, Ahmad A. Tarhini, Caroline Chung, David A. Reardon, Piyush Durani, Peter A. Forsyth, Reena Thomas, Sekwon Jang, M. S. Ernstoff, Corey Ritchings, Michael B. Atkins
Publikováno v:
The Lancet. Oncology, vol 22, iss 12
Lancet Oncol
Lancet Oncol
Summary Background Combination nivolumab plus ipilimumab was efficacious in patients with asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low efficacy in patients with symptomatic MBM. Here, we provide final 3-year follow-up
Autor:
Melinda L. Yushak, Jim Zhong, David H. Lawson, David C. Qian, Brianna Brammer, Chrystal M. Paulos, Mohammad K. Khan, James Janopaul-Naylor, Troy Kleber, Jeffrey M. Switchenko, R. Donald Harvey, Karen M. Xu, Zachary S. Buchwald, Ragini R. Kudchadkar
Publikováno v:
The Lancet. Oncology. 22(12)
Summary Background The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications. We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infu
Autor:
Ragini R. Kudchadkar, Uwe M. Martens, Paul Nghiem, Robert L. Ferris, Julie E. Stein, Junchen Gu, Suzanne L. Topalian, Michi M. Shinohara, Adam Barrows, Christine H. Chung, Rima M. Kulikauskas, Jean Pierre Delord, Lara Dunn, Andrea Horvath, Janis M. Taube, Shailender Bhatia, Lot A. Devriese, William H. Sharfman, Bin Li, Céleste Lebbé, Tian Chen, Asim Amin, Elizabeth L. Engle, Christopher D. Lao
Publikováno v:
J Clin Oncol
PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and
Autor:
Steven P. Fling, Daniel L. Barber, Vanessa Raabe, Paul Nghiem, David Ashkin, Ragini R. Kudchadkar, Jonathan Cheng, Tracey A. Day, Shunsuke Sakai, Julie Vergara, Martin A. Cheever, Elad Sharon, Lisa Lundgren, Jorge Nieva, Colleen S. Kraft
Publikováno v:
Sci Transl Med
Because of the well-established therapeutic benefit of boosting antitumor responses through blockade of the T cell inhibitory receptor PD-1, it has been proposed that PD-1 blockade could also be useful in infectious disease settings, including Mycoba
Autor:
Anna C. Pavlick, Reena Thomas, Peter A. Forsyth, Hussein Abdul-Hassan Tawbi, F. Stephen Hodi, David A. Reardon, Omid Hamid, Karl D. Lewis, Joel Jiang, Alain Algazi, Michael B. Atkins, Sheena Demelo, Kim Margolin, Marc S. Ernstoff, Igor Puzanov, Christopher D. Lao, Ahmad A. Tarhini, Stergios J. Moschos, Ragini R. Kudchadkar, Nikhil I. Khushalani, Alexandre Avila, Michael A. Postow
Publikováno v:
The New England journal of medicine, vol 379, iss 8
BackgroundBrain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma have excluded patients with untreated br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9842d318557841dc70e5ef68e3840d40
https://escholarship.org/uc/item/41x6h654
https://escholarship.org/uc/item/41x6h654